Acamprosate

Limits on what this shows

• Key negative/null findings: None identified; no study has tested whether this in vitro effect reproduces in whole animals or in humans at therapeutic exposure.
• At-risk subgroups: None established in humans. Severe renal impairment raises plasma exposure (see Pharmacokinetic basis), which is noted here only as a plausibility consideration, not a demonstrated risk.

Regulatory status

Not addressed in the FDA label. The label's own PK data (no metabolism, no CYP450 activity) offer no independent mitochondrial-toxicity signal.

Population evidence

Tier B, in vitro only. Sahdeo et al. 2014 screened FDA-approved drugs on oxygen-biosensor plates in RGC-5 (retinal ganglion) cells; acamprosate at 10 micromolar reduced oxygen consumption to a fold-change-from-vehicle of 0.65 +/- 0.14 at 2 hours and 0.36 +/- 0.16 at 24 hours and was classified by the authors as a mitochondrial inhibitor. For scale, the labeled standard-dose human plasma Cmax (about 350 ng/mL) corresponds to roughly 1.9 micromolar; the 10 micromolar test concentration is well above typical therapeutic exposure, though severe renal impairment (about 4-fold Cmax elevation per the label) would still fall short of it.

Mechanism

Named but hypothesized, not confirmed: the authors propose that acamprosate's known inhibition of microsomal Ca2+-ATPase raises reactive oxygen species, secondarily impairing mitochondrial function. Shares its evidentiary basis with the ATP production entry below (see Overlap map) and shares its proposed mechanism with the Oxidative stress entry below.

Counter-evidence held on record

Single in vitro study, one cell line, no replication, and a test concentration above standard-dose human plasma levels. This is a cell-culture finding at a supraphysiologic concentration, not a demonstrated effect in treated patients. It must never be presented as measured mitochondrial harm from taking acamprosate, and no supplement or dose is recommended on the strength of it.

Limits on what this shows

• Key negative/null findings: None identified in the sources accessed.
• At-risk subgroups: None established in humans; both supporting sources are rodent brain-tissue studies.

Regulatory status

Not addressed in the FDA label.

Population evidence

Tier B, animal only. Caliskan et al. 2010 randomized 40 male rats to control, ethanol, acamprosate-only, and acamprosate-plus-ethanol groups for 21 days. The acamprosate-only group showed further increased lipid peroxidation and decreased brain antioxidant vitamin levels versus control, alongside altered hippocampal NMDA receptor subunits and brain microsomal Ca2+-ATPase activity. A second, independent rat study (Ewertowska et al. 2015) examined antioxidant-defense-system responses to acamprosate in ethanol-preferring versus non-preferring rats; this review confirmed its title, authors, and Tier B (drug-specific, animal) status via the PubMed record, but rate-limiting prevented retrieval of its full abstract before this session's access was lost (see Sources), so only its existence is relied upon here, not a specific direction or magnitude from it.

Mechanism

Named, hypothesized: Ca2+-ATPase inhibition raising reactive oxygen species. Shares this proposed mechanism with the Mitochondrial burden entry above, drawn from a second, independent study (see Overlap map).

Counter-evidence held on record

No human plasma or tissue antioxidant marker has been measured in acamprosate-treated patients in the literature accessed during this review. An animal brain-tissue finding, not a demonstrated effect in human patients. Never state this as "acamprosate causes oxidative stress" without the animal-only qualifier.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B/C evidence located and no circulating claim identified to rebut.

Channels tried

PubMed ("acamprosate copper"): clean zero, 0 hits, no automatic term-mapping fallback triggered, a true zero rather than a blocked attempt. Repeated independently in a later repair pass with the identical result: clean zero again, confirming the first pass. A further repair-pass phrasing ("acamprosate AND (ceruloplasmin OR trace element OR trace metal)") was attempted but returned HTTP 429 before results loaded. Europe PMC REST API: HTTP 429 (rate-limited) when queried for this category in both passes. OpenAlex search endpoint: HTTP 429 in the first pass, refused outright at the network/gateway level (HTTP 403 on CONNECT) in the repair pass. Semantic Scholar API: HTTP 429 in the first pass, refused at the network/gateway level (HTTP 403 on CONNECT) in the repair pass. Crossref REST API: blocked at the network/gateway level in both passes (HTTP 403 on CONNECT, confirmed via the agent proxy's own status check), not merely rate-limited. DailyMed/FDA label: reviewed directly in full; no copper-related content of any kind.

Assessment

Best read as a genuine literature gap, now corroborated by two independent, non-blocked clean-zero PubMed results across two separate review passes, with residual uncertainty contributed by the gateway-blocked and rate-limited channels.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B/C evidence located and no circulating claim identified to rebut.

Channels tried

PubMed ("acamprosate iron"): 1 hit returned (an amyloid-precursor-protein/iron-chelation paper in Alzheimer's disease, PMID 30470799); opened and checked against the cohort test, it has no alcohol-use-disorder or acamprosate-treated cohort and does not evaluate acamprosate's effect on iron status, so it was excluded. A later repair-pass broadened query ("acamprosate AND (iron OR ferritin OR transferrin)") returned 3 hits: the same APP paper (excluded as above); a double-blind, placebo-controlled acamprosate relapse-prevention trial in Spain (Gual and Lehert 2001, PMID 11524307) whose abstract was opened in full via Europe PMC and reports abstinence-duration outcomes and unspecified drinking-related biochemical markers, with no mention anywhere of iron, ferritin, transferrin, or hemoglobin, so it does not support an iron finding despite matching the search term; and a methodology paper on choice of drinking-outcome variables in the unrelated COMBINE Study, returned only as a title because Europe PMC was rate-limited (HTTP 429) before its abstract could be opened, so it is disclosed as an unopened, title-level match and is not cited as a checked source. Europe PMC: reachable for the Gual lookup, then HTTP 429 on the COMBINE-study record and all further attempts. OpenAlex and Semantic Scholar: refused at the network/gateway level (HTTP 403 on CONNECT) in the repair pass. Crossref: blocked at the network/gateway level across both passes (HTTP 403 on CONNECT). DailyMed/FDA label: reviewed directly in full; no iron-related content.

Assessment

Genuine literature gap for this drug specifically across two review passes; every candidate located either failed the cohort/relevance test on a source actually opened and read, or remains an unopened title-level match disclosed as such rather than cited as evidence.

Limits on what this shows

• Key negative/null findings: Anorexia was not increased over placebo (3% vs 3%), arguing against an appetite/intake-driven pathway as a contributor; this does not bear on the motility-driven pathway described above.
• At-risk subgroups: Patients who discontinue for diarrhea (2%) represent the clearest dose-related signal; the higher 1998 mg/day dose shows the higher rate (17% vs 10%).

Regulatory status

FDA label, pooled adverse-reaction tables: diarrhea in 16% of acamprosate-treated patients overall (10% at 1332 mg/day, 17% at 1998 mg/day) versus 10% on placebo; discontinuation for diarrhea in 2% of acamprosate-treated versus 0.7% of placebo-treated patients.

Population evidence

Tier A for the diarrhea finding itself (randomized, placebo-controlled registration trials, acamprosate in the cohort). The step from diarrhea to "gut microbiome risk" is a mechanistic inference only (Tier C-level reasoning): no study located in the channels accessed has directly assayed microbiome composition or diversity in acamprosate-treated patients.

Mechanism

Altered GI transit time/motility is a generally accepted route to microbiome compositional change in gut physiology broadly; this is general physiology, not an acamprosate-specific microbiome finding.

Counter-evidence held on record

A review of alcohol use disorder and gut microbiota (Wang et al. 2020) was located but addresses alcohol's own, disease-intrinsic effect on gut microbiota, not acamprosate's; it does not meet the cohort test for this drug and is not used to support this entry (see Scope and limits on disease-intrinsic versus drug-caused effects). Based on a labeled GI side effect, not a direct microbiome measurement. Never state that acamprosate has been shown to alter the gut microbiome.

Limits on what this shows

• Key negative/null findings: None identified; no direct ATP assay for this drug was located in any system.
• At-risk subgroups: None established.

Regulatory status

Not addressed in the FDA label.

Population evidence

Tier B, in vitro. Sahdeo et al. 2014 classified acamprosate as a mitochondrial respiratory inhibitor in RGC-5 cells at 10 micromolar (see Mitochondrial burden entry). Because oxygen consumption in coupled mitochondria is tightly linked to oxidative-phosphorylation ATP output, a reduction in oxygen consumption is mechanistically consistent with reduced ATP synthesis, though the study did not directly assay ATP, ADP/ATP ratio, or any other energy-charge marker.

Mechanism

Inferred, not directly measured: the authors classified acamprosate as an inhibitor of respiration rather than an uncoupler, which would be expected to reduce coupled ATP synthesis rather than dissipate the proton gradient without ATP production.

Counter-evidence held on record

This entry rests entirely on an inference from the oxygen-consumption data cited under Mitochondrial burden (see Overlap map), not an independent ATP measurement. Inferred from an oxygen-consumption proxy at a single supraphysiologic in vitro concentration, not a measured ATP effect. Do not present as a demonstrated cellular energy deficit, and weight it alongside Mitochondrial burden as one line of evidence, not two.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B/C evidence located and no circulating claim identified to rebut.

Channels tried

PubMed ("acamprosate hemoglobin"): clean zero, 0 hits, a true zero. A broader OR-combined query ("acamprosate anemia OR hemoglobin OR hematocrit") was also attempted but was mis-parsed by PubMed's query interpreter into an unrelated, very large result set and is not treated as informative either way. A later repair-pass query ("acamprosate AND (hemoglobin OR hematocrit OR anemia OR oxygen)") correctly parsed and returned 7 hits, each checked against this category's definition (hemoglobin, hematocrit, red-cell mass, arterial oxygenation, tissue oxygen delivery): an acamprosate-specific rat study on reactive-oxygen-species reduction addresses intracellular oxidative stress, not systemic oxygen delivery, and falls outside this category's scope (it would belong under Oxidative stress, which is outside this repair's scope and was not reopened); the Sahdeo et al. 2014 mitochondrial-oxygen-biosensor study, already cited under Mitochondrial burden and ATP production, measures cellular oxygen consumption during mitochondrial respiration rather than hemoglobin-mediated oxygen delivery, so it does not qualify here either, and reusing it would double-count one data point across three entries; a title-level match on an acamprosate-plus-diazepam rat study of ethanol-vapour-induced cortical and behavioural alterations could not be opened after repeated HTTP 429 responses across multiple attempts, so it is disclosed as an unopened lead, not evidence; the acamprosate/tinnitus, acamprosate/Parkinson's-combination, and acamprosate-nanoparticle-cytotoxicity results show no apparent relevance to systemic oxygen delivery on their titles and were not opened. DailyMed/FDA label adverse-reaction data reviewed directly in full: no anemia, hemoglobin, or hematocrit signal of any kind is listed among labeled adverse reactions. Europe PMC, OpenAlex, Semantic Scholar: rate-limited (HTTP 429) or refused at the network/gateway level (HTTP 403) on every attempt in the repair pass. Crossref: blocked at the network/gateway level across both passes.

Assessment

Best read as a genuine literature and labeling gap for this drug, corroborated by a clean PubMed zero and a full direct read of the label's adverse-reaction data. One unopened, potentially relevant lead (the acamprosate-plus-diazepam ethanol-vapour rat study) should be the first thing re-checked when access improves, ahead of a fresh broad search.